Statements

Therapeutic response

Precision oncology relationships for therapeutic response.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Afatinib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	FDA
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	CD19 +, not BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	FDA
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	FDA
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	FDA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	FDA
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	FDA
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	FDA
Sensitivity (Supports)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	FDA
Sensitivity (Supports)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab	FDA
Sensitivity (Supports)	dMMR	Any solid tumor	Dostarlimab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant	FDA
Sensitivity (Supports)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib	FDA
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant	FDA
Sensitivity (Supports)	FGFR2::v	Intrahepatic Cholangiocarcinoma	Futibatinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib	FDA
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Gilteritinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (Supports)	not KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	FDA
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	FDA
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (Supports)	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Infigratinib	FDA
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	FDA
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	FDA
Sensitivity (Supports)	5q deletion	Myelodysplastic Syndromes	Lenalidomide	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Eribulin, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Gemcitabine, Margetuximab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Margetuximab, Vinorelbine	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Neratinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib	FDA
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	FDA
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	FDA
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab	FDA
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed	FDA
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	dMMR	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	FDA
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-L	Endometrial Carcinoma	Lenvatinib, Pembrolizumab	FDA
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	TMB-H (>= 10 mutations / Mb)	Any solid tumor	Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab	FDA
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib	FDA
Sensitivity (Supports)	FGFR1 rearrangements	Myeloid/Lymphoid Neoplasms	Pemigatinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	FDA
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine	FDA
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	FDA
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	FDA
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Pralsetinib	FDA
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Pralsetinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Repotrectinib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	FDA
Sensitivity (Supports)	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib	FDA
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	FDA
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	FDA
Sensitivity (Supports)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib	FDA
Sensitivity (Supports)	v::RET	Anaplastic Thyroid Cancer	Selpercatinib	FDA
Sensitivity (Supports)	v::RET	Any solid tumor	Selpercatinib	FDA
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	FDA
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	ERBB2 activating variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib	FDA
Sensitivity (Supports)	EZH2 p.Y646N	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646F	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646H	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646S	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.Y646C	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.A682G	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	EZH2 p.A692V	Follicular Lymphoma	Tazemetostat	FDA
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	TSC1 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (Supports)	TSC2 oncogenic variants	Renal Angiomyolipoma	Everolimus	FDA
Sensitivity (Supports)	TSC1 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus	FDA
Sensitivity (Supports)	TSC2 oncogenic variants	Subependymal Giant Cell Astrocytoma	Everolimus	FDA
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	FDA
Sensitivity (Supports)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine	FDA
Sensitivity (Supports)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed	FDA
Sensitivity (Supports)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab	FDA
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Nivolumab	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	FDA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	FDA
Sensitivity (Supports)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab	FDA
Sensitivity (Supports)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab	FDA
Sensitivity (Supports)	HER2-positive	Cholangiocarcinoma	Zanidatamab	FDA
Sensitivity (Supports)	v::NRG1	Non-Small Cell Lung Cancer	Zenocutuzumab	FDA
Sensitivity (Supports)	v::NRG1	Pancreatic Adenocarcinoma	Zenocutuzumab	FDA
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ensartinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab	FDA
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (Supports)	t(KMT2A;v)	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	FDA
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab	FDA
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Taletrectinib	FDA
Sensitivity (Supports)	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin	FDA
Sensitivity (Supports)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (Supports)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib	FDA
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	FDA
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	FDA
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	HER2-negative, PR positive	Non-Small Cell Lung Cancer	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Datopotamab deruxtecan	FDA
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib	FDA
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib	FDA
Sensitivity (Supports)	H3-3A p.K28M	Diffuse Midline Glioma	Dordaviprone	FDA
Sensitivity (Supports)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant	FDA
Sensitivity (Supports)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib	FDA
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib	FDA
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib	FDA
Sensitivity (Supports)	not 17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib	FDA
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib	FDA
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab deruxtecan	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab	FDA
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Lymphoid Leukemia	Revumenib	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Burkitt Lymphoma	Revumenib	FDA
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Leukemias of Ambiguous Lineage	Revumenib	FDA
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	FDA
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Irinotecan	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab	FDA
Sensitivity (Supports)	VHL pathogenic variants	Renal Cell Carcinoma	Belzutifan	FDA
Sensitivity (Supports)	VHL pathogenic variants	Central Nervous System Hemangioblastoma	Belzutifan	FDA
Sensitivity (Supports)	VHL pathogenic variants	Pancreatic Neuroendocrine Tumor	Belzutifan	FDA
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (Supports)	CD30 +	Angioimmunoblastic T-Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (Supports)	CD30 +	Peripheral T-Cell lymphoma, NOS	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (Supports)	CD30 +	Mycosis Fungoides	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib	HC
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib	HC
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib	HC
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin	HC
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib	HC
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan	HC
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan	HC
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan	HC
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan	HC
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant	HC
Sensitivity (Supports)	EGFR Somatic variants	Non-Small Cell Lung Cancer	Afatinib	HC
Sensitivity (Supports)	EGFR activating variants	Non-Small Cell Lung Cancer	Afatinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (Supports)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (Supports)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (Supports)	not KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	HC
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	HC
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Paclitaxel, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib	HC
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	HC
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab	HC
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (Supports)	EGFR TKD activating variants	Non-Small Cell Lung Cancer	Gefitinib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib	HC
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab	HC
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Dostarlimab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Pembrolizumab	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab	HC
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab	HC
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab	HC
Sensitivity (Supports)	dMMR	Any solid tumor	Pembrolizumab	HC
Sensitivity (Supports)	MSI-H	Any solid tumor	Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	HC
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab	HC
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab	HC
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib	HC
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib	HC
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib	HC
Sensitivity (Supports)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin	HC
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Nivolumab	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Nivolumab	HC
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	HC
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab	HC
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab	HC
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Pemigatinib	HC
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab	HC
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib	HC
Sensitivity (Supports)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib	HC
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Selpercatinib	HC
Sensitivity (Supports)	5q deletion	Myelodysplastic Syndromes	Lenalidomide	HC
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab	HC
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab	HC
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine	HC
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine	HC
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine	HC
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib	HC
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib	HC
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib	HC
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed	HC
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab	HC
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin	HC
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib	HC
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib	HC
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	HC
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed	HC
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed	HC
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib	HC
Sensitivity (Supports)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab	HC
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel	HC
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib	HC
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib	HC
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan	HC
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 Somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 Somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib	HC
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib	HC
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane	HC
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib	HC
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib	HC
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib	HC
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib	HC
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib	HC
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib	HC
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib	HC
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Gilteritinib	HC
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab	HC
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed	HC
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab	HC
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib	HC
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Vemurafenib	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	HC
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	HC
Sensitivity (Supports)	HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	HC
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA Somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	HC
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib	HC
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	HC
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib	HC
Sensitivity (Supports)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan	HC